Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Influenza new coronary combined vaccine and preparation method thereof

A combined vaccine and influenza technology, applied in biochemical equipment and methods, vaccines, multivalent vaccines, etc., to achieve good compatibility, high safety, and high cost-effectiveness.

Active Publication Date: 2021-12-03
天津中逸安健生物科技有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Aluminum adjuvant is a classic human influenza vaccine adjuvant, which can increase the titer of antigen-specific antibodies and induce a strong humoral immune response. However, the application of aluminum adjuvant in influenza-Covid-19 combined vaccine has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Influenza-COVID-19 combined vaccine, including raw materials with the following mass concentrations: recombinant COVID-19 vaccine containing RBD-Fc fusion protein, with a mass concentration of 80 μg / mL; influenza subunit vaccine containing H1N1 influenza virus, with a mass concentration of 18 μg / mL; containing H3N2 Influenza subunit vaccine of type B influenza virus, the mass concentration is 18μg / mL; Influenza virus subunit vaccine containing type B influenza virus, the mass concentration of influenza virus subunit vaccine is 18μg / mL; aluminum hydroxide solution, aluminum ion in the combination of influenza and new crown The final concentration in the vaccine is 0.6 mg / mL; the balance is PBS phosphate buffer.

[0040] The preparation method of the above-mentioned influenza and new crown combined vaccine specifically comprises the following steps:

[0041] (1) Weigh each raw material according to the mass fraction of the above-mentioned combined influenza and COVID-19 vac...

Embodiment 2

[0054] Influenza-COVID-19 combined vaccine, including raw materials with the following mass concentrations: recombinant COVID-19 vaccine containing RBD-Fc fusion protein, with a mass concentration of 5 μg / mL; influenza subunit vaccine containing H1N1 influenza virus, with a mass concentration of 20 μg / mL; containing H3N2 Influenza subunit vaccine of Type B influenza virus, mass concentration is 20 μg / mL; Influenza virus subunit vaccine containing influenza virus type B, mass concentration is 20 μg / mL; Aluminum hydroxide solution, the final concentration of aluminum ion is 0.6mg / mL; the balance is PBS phosphate buffer.

[0055] The preparation method of the above-mentioned influenza and new crown combined vaccine specifically comprises the following steps:

[0056] (1) Weigh each raw material according to the mass fraction of the above-mentioned combined influenza and COVID-19 vaccine;

[0057] Wherein, the preparation method of aluminum hydroxide solution is:

[0058] ① Weig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses an influenza new coronary combined vaccine. The influenza new coronary combined vaccine is prepared from the following raw materials in mass concentration: 1 to 100 micrograms / mL of recombinant new coronary vaccine containing RBD-Fc fusion protein, 1 to 50 micrograms / mL of influenza subunit vaccine containing H1N1 type influenza virus, 1 to 50 micrograms / mL of influenza subunit vaccine containing H3N2 type influenza virus, 1 to 50 micrograms / mL of influenza subunit vaccine containing B type influenza virus, an aluminum hydroxide solution and the balance of PBS phosphate buffer, wherein the final concentration of aluminum ions in the influenza new coronary combined vaccine is 0.5 to 2.0mg / mL. A preparation method comprises the following steps of: weighing all the raw materials; diluting the four vaccines with the PBS phosphate buffer respectively and then mixing with the aluminum hydroxide solution; and mixing according to an equal volume ratio to obtain the influenza new coronary combined vaccine. The influenza new coronary combined vaccine disclosed by the invention is a combined vaccine of a novel coronavirus vaccine containing an aluminum adjuvant and the influenza subunit vaccine containing the aluminum adjuvant; and after combination, the two antigen component vaccines are not mutually inhibited and can be very well compatible.

Description

technical field [0001] The invention relates to the technical field of biological products, and more specifically relates to a combined influenza and new crown vaccine and a preparation method thereof. Background technique [0002] COVID-19 spreads rapidly and has a high case fatality rate, and an effective vaccine is urgently needed to control the pandemic. [0003] As of December 2020, there are 60 vaccines based on six different technical routes, including inactivated vaccines, nucleic acid vaccines (including DNA vaccines and mRNA vaccines), vector vaccines, protein subunit vaccines, live attenuated vaccines, and virus-like particle vaccines. 3 candidate vaccines have been approved to enter clinical trials, and 7 vaccines (3 inactivated vaccines, 2 mRNA nucleic acid vaccines, and 2 vector vaccines) have been approved for emergency use or qualified for marketing. [0004] At present, a total of 18 new coronavirus protein subunit vaccines have entered clinical trials, acc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/295A61K39/215A61K39/145A61K39/39A61P31/14A61P31/16
CPCA61K39/12A61K39/39A61P31/14A61P31/16A61K2039/70A61K2039/55505C12N2760/16234C12N2760/16134C12N2770/20034
Inventor 阮承迈高春润刘淑惠高辉李新旺高金榜张靖丽崔艳李凤凯
Owner 天津中逸安健生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com